Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

LIPO

Lipella Pharmaceuticals Inc

Dec 11 • 04:00PM ET

3.02

Dollar change +0.03
Percentage change 1.00	%

Healthcare • Biotechnology • USA • NASD

Peers: VKTX EBS EYPT CARA PTGX SCYX GOSS CPIX UBX HOOK

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.50	Insider Own	29.38%	Shs Outstand	1.09M	Perf Week	9.03%
Market Cap	3.65M	Forward P/E	-	EPS next Y	-5.20	Insider Trans	0.00%	Shs Float	0.85M	Perf Month	-5.92%
Income	-4.26M	PEG	-	EPS next Q	-2.43	Inst Own	0.88%	Short Float	1.89%	Perf Quarter	-0.05%
Sales	0.48M	P/S	7.60	EPS this Y	-27.44%	Inst Trans	-	Short Ratio	0.08	Perf Half Y	-42.73%
Book/sh	1.34	P/B	2.26	EPS next Y	33.76%	ROA	-170.50%	Short Interest	0.02M	Perf Year	-64.72%
Cash/sh	1.12	P/C	2.70	EPS next 5Y	-	ROE	-231.67%	52W Range	2.21 - 12.00	Perf YTD	-62.99%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-190.11%	ROI	-292.24%	52W High	-74.83%	Beta	0.38
Dividend TTM	-	Quick Ratio	2.97	Sales past 5Y	20.14%	Gross Margin	99.40%	52W Low	36.65%	ATR (14)	0.35
Dividend Ex-Date	-	Current Ratio	2.97	EPS Y/Y TTM	24.79%	Oper. Margin	-901.46%	RSI (14)	52.40	Volatility	11.93% 12.32%
Employees	7	Debt/Eq	0.05	Sales Y/Y TTM	0.78%	Profit Margin	-881.73%	Recom	1.00	Target Price	10.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	29.85%	Payout	-	Rel Volume	0.30	Prev Close	2.99
Sales Surprise	0.00%	EPS Surprise	0.00%	Sales Q/Q	-22.75%	Earnings	Nov 27	Avg Volume	201.56K	Price	3.02
SMA20	9.25%	SMA50	-1.56%	SMA200	-31.85%	Trades		Volume	60,116	Change	1.00%

Dec-03-24 08:30AM	Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus (GlobeNewswire) -8.20%
Nov-21-24 05:30AM	Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group (GlobeNewswire)
Nov-12-24 05:30AM	Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform (GlobeNewswire) -8.10%
Nov-01-24 04:30PM	Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split (GlobeNewswire) -12.80%
Oct-29-24 08:30AM	Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference (GlobeNewswire)
05:00AM	Loading…
Oct-15-24 05:00AM	Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform (GlobeNewswire) +5.21%
Oct-09-24 10:47AM	Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-25-24 08:30AM	PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month (GlobeNewswire)
Sep-24-24 08:00AM	Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus (GlobeNewswire) +10.32%
Aug-27-24 08:00AM	Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York (GlobeNewswire)
Aug-22-24 05:00AM	Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research (GlobeNewswire)
Aug-21-24 05:00AM	Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference (GlobeNewswire)
Aug-12-24 06:52AM	Lipella doses first two subjects in Phase IIa oral lichen planus treatment trial (Clinical Trials Arena)
05:00AM	Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial (GlobeNewswire)
Aug-01-24 04:05PM	Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -9.05% -5.67%
08:00AM	Loading…
08:00AM	Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Jul-29-24 05:00AM	Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients (GlobeNewswire) +122.52%
May-31-24 08:00AM	Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus (GlobeNewswire)
May-29-24 12:53PM	LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q1 2024 (InvestorPlace)
08:00AM	Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-24-24 01:53PM	LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q4 2023 (InvestorPlace)
May-21-24 08:00AM	Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b (GlobeNewswire)
Apr-17-24 08:00AM	Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise (GlobeNewswire)
Apr-05-24 08:00AM	Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024 (GlobeNewswire)
Apr-03-24 08:00AM	Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis (GlobeNewswire)
Mar-07-24 03:23PM	PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease (GlobeNewswire)
Mar-05-24 08:00AM	Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline (GlobeNewswire) -21.57%
Feb-20-24 08:00AM	Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference (GlobeNewswire)
Dec-20-23 08:00AM	Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished (GlobeNewswire)
Nov-12-23 08:20PM	Lipella Pharmaceuticals gets ODD for LP-310 to treat GvHD (Pharmaceutical Business Review)
08:00AM	Loading…
Nov-10-23 08:00AM	FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease (PR Newswire) -8.12%
Oct-25-23 04:05PM	Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire) -24.89% -31.95%
Oct-24-23 08:00AM	Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Oct-23-23 08:45AM	Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing (PR Newswire)
08:30AM	Lipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference (ACCESSWIRE)
Oct-20-23 08:00AM	Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus (PR Newswire) +29.81%
Sep-21-23 08:30AM	Lipella Pharmaceuticals' Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology (PR Newswire)
Jun-13-23 08:30AM	Lipella Pharmaceuticals: Addressing Significant Unmet Need for Cancer Survivors, Delivering Long Term Value for Shareholders (NewMediaWire) +6.75%
May-15-23 09:15AM	Lipella Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update (PR Newswire)
May-14-23 08:12AM	Lipella Pharmaceuticals First Quarter 2023 Earnings: US$0.19 loss per share (vs US$0.19 loss in 1Q 2022) (Simply Wall St.)
May-01-23 08:30AM	Lipella Pharmaceuticals Delivers Late-Breaking Presentation at the American Urological Association Annual Meeting (PR Newswire) -20.90%
Apr-17-23 08:30AM	Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite (PR Newswire)
Apr-05-23 08:30AM	Lipella Pharmaceuticals Doses First Patient in Human Study of Innovative Contrast Agent (PR Newswire)
Mar-31-23 08:00AM	Lipella Provides Business Update and Reports 2022 Financial Results (PR Newswire) +5.98%
Mar-16-23 08:30AM	Lipella Pharmaceuticals Successfully Completes Phase 2a Clinical Trial; Announces Late-Breaking Presentation at the Annual Meeting of the American Urological Association (PR Newswire) +36.07%
Mar-01-23 08:00AM	Lipella Pharmaceuticals Announces Creation of Oral Health Scientific Advisory Board (PR Newswire)
Jan-11-23 07:30AM	Lipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10 (PR Newswire) +18.01%
Jan-09-23 08:00AM	Lipella Pharmaceuticals to Present at January 2023 Biotech Showcase in San Francisco (PR Newswire)
Dec-22-22 04:05PM	Lipella Announces Closing of Initial Public Offering for Gross Proceeds of $7 Million (PR Newswire) +12.78% -10.89%

Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. It offers LP-08 which consists of Sphingomyelin Phospholipid bilayers separated by aqueous compartments, LP-09, a liposomal formulation of Botulinum toxin, and LP-10, a proprietary liposomal formulation of Tacrolimus, a potent immunosuppressant and anti-inflammatory agent. The company was founded by Jonathan Kaufman and Michael Chancellor on February 15, 2005 and is headquartered in Pittsburgh, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kaufman Jonathan H	See remarks below.	May 14 '24	Buy	0.76	10,000	7,590	898,849	May 15 04:39 PM
Kaufman Jonathan H	See remarks below.	Mar 18 '24	Buy	0.79	30,000	23,649	863,849	Mar 19 06:21 PM
Kaufman Jonathan H	See remarks below.	Mar 19 '24	Buy	0.87	25,000	21,802	888,849	Mar 19 06:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LIPO

Lipella Pharmaceuticals Inc

Upgrade your FINVIZ experience